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3+ntravascular hemolysis can occur in a number of diseases,
ncluding sepsis, malaria and the hemolytic anemias [sickle
ell disease (SCD), paroxysmal nocturnal hemoglobinuria,
tc.], as well as following certain events such as mismatched
ransfusions. The pathophysiological signiﬁcance of intravas-
ular hemolysis had been largely ignored in diseases such
s SCD save for its effect on red cell numbers, however, rel-
tively recent studies have shed light on the major effects
hat hemolytic processes have on vascular biology, particularly
n the endothelium, inﬂammatory processes and oxidative
tress.
Under normal circumstances, hemoglobin (Hb) is con-
ained in the red blood cells (RBCs), and employed primarily
or oxygen transport. However, the destruction of RBC (i.e.
emolysis) results in the release of Hb into the circulation.
f this hemoglobin is not neutralized immediately into less
oxic metabolites by specialized scavenger proteins, such as
aptoglobin and hemopexin, as can occur when extensive
emolysis overwhelms innate protective mechanisms, this
ell-free Hb causes chaos.1 The potential extent of this dam-
ge was perhaps ﬁrst recognized when Reiter et al.2 showed
hat the decompartmentalization of Hb into the plasma
igniﬁcantly impairs vascular nitric oxide (NO) bioavailabil-
ty, potentially facilitating vasoconstriction and alterations
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eserved.in blood ﬂow, as well as inducing endothelial dysfunction
and platelet activation.3,4 While the contribution of hemol-
ysis and subsequent NO depletion to manifestations of SCD,
such as pulmonary hypertension, has been disputed,5 more
recent evidence has highlighted the signiﬁcant effects that
intravascular hemolysis has on inﬂammatory processes. The
induction of acute hemolytic events in C57BL/6 mice (using
intravenous water injections, resulting in plasma levels of cell-
free Hb that were similar to those seen in mice with SCD) was
found to induce a rapid and extensive systemic and vascu-
lar inﬂammatory response (within 15 min). This is possibly
mediated by vascular NO consumption, and leads to extensive
systemic inﬂammation (Figure 1) and leukocyte recruitment
to the blood vessels.6 Given the evidence that inﬂammation
and leukocyte adhesion to the endothelium can initiate and
propagate vaso-occlusive processes,7,8 it is reasonable to con-
clude that vascular inﬂammatory processes that are triggered
by acute intravascular hemolytic events may be of pathophy-
siological signiﬁcance in SCD as well as in the other diseases
or medical events in which they occur.
Once oxyhemoglobin has reacted with NO in the bloodversidade Estadual de Campinas (Unicamp), Rua Carlos Chagas,
vessel, Hb-Fe is formed and can accumulate both in the cir-
culation and in tissues.9 In a secondary Hb-mediated toxic
mechanism, Hb-Fe3+ releases damaging hemin, a hydrophobic
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Figure 1 – Quantiﬁcation of systemic inﬂammation in vivo using the IVIS Lumina System® (Caliper LifeSciences, MA).
Images obtained 15 min  after intravenous injections of saline or water (150 L) in C57BL/6 mice and a chimeric sickle cell
disease mouse. A chemiluminescent probe (XenoLight Rediject Inﬂammation Probe; Perkin Elmer, MA)  was injected in the
mouse to quantify myeloperoxidase production of activated phagocytes and neutrophils. Similar data were  originally
reported in reference 6.
rmolecule shown to induce neutrophil extracellular trap (NET)
production, stimulate inﬂammasome formation and cause
toll-like receptor (TLR)-4-mediated vaso-occlusion in mice
with SCD, as well as lipoprotein oxidation.10–13 These sec-
ondary inﬂammatory and oxidative effects of hemin appear
to occur in a less immediate,6 but probably more  sustained
manner, causing tissue damage and endothelial dysfunction,
as well as sustaining leukocyte activation in the blood vessels.9
Hemolysis, therefore, represents a major disease mecha-
nism and failure to neutralize Hb after its release from the RBC
can result in vascular inﬂammation and organ dysfunction,
potentially contributing to clinical complications that have
been associated with hemolytic diseases, such as priapism,
pulmonary hypertension and leg ulcers.14
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